HealthDay - FRIDAY, Sept. 14 (HealthDay News) -- The Eli Lilly drug Evista(raloxifene) has been approved by the U.S. Food and Drug Administration toreduce the risk of invasive breast cancer among postmenopausal at highrisk for the disease and among postmenopausal women with osteoporosis.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.